肾移植治疗厄德海姆-切斯特病。

Case Reports in Transplantation Pub Date : 2020-07-13 eCollection Date: 2020-01-01 DOI:10.1155/2020/3954165
Jongwon Yoo, Cynthia Gunsteen, Sima Patel, Ted Clevy-Schneller, Sucha Nand, Divya Jain, Raquel Garcia-Roca, Amishi Desai, Sanjeev Akkina
{"title":"肾移植治疗厄德海姆-切斯特病。","authors":"Jongwon Yoo,&nbsp;Cynthia Gunsteen,&nbsp;Sima Patel,&nbsp;Ted Clevy-Schneller,&nbsp;Sucha Nand,&nbsp;Divya Jain,&nbsp;Raquel Garcia-Roca,&nbsp;Amishi Desai,&nbsp;Sanjeev Akkina","doi":"10.1155/2020/3954165","DOIUrl":null,"url":null,"abstract":"<p><p>Erdheim-Chester disease is a rare inflammatory disease that infiltrates skeletal and extra-skeletal tissue. Chronic kidney disease (CKD) in Erdheim-Chester disease is usually attributed to retroperitoneal lesions that lead to urologic obstruction and hydronephrosis. In this report, we describe a patient diagnosed with Erdheim-Chester disease who eventually developed end-stage kidney disease (ESKD). After complete remission of Erdheim-Chester disease by vemurafenib therapy and 2 years of hemodialysis, the patient underwent a deceased donor kidney transplantation with basiliximab induction and tacrolimus/mycophenolic acid maintenance. After conversion of mycophenolic acid to azathioprine due to cost, acute cellular rejection had occurred, and he was treated with steroid therapy. The patient remained in complete remission from Erdheim-Chester disease and dialysis-free 16 months after transplant. Kidney transplantation is another treatment option for those patients with Erdheim-Chester disease who suffer from renal failure in the setting of complete remission.</p>","PeriodicalId":30327,"journal":{"name":"Case Reports in Transplantation","volume":"2020 ","pages":"3954165"},"PeriodicalIF":0.0000,"publicationDate":"2020-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/3954165","citationCount":"7","resultStr":"{\"title\":\"Kidney Transplantation for Erdheim-Chester Disease.\",\"authors\":\"Jongwon Yoo,&nbsp;Cynthia Gunsteen,&nbsp;Sima Patel,&nbsp;Ted Clevy-Schneller,&nbsp;Sucha Nand,&nbsp;Divya Jain,&nbsp;Raquel Garcia-Roca,&nbsp;Amishi Desai,&nbsp;Sanjeev Akkina\",\"doi\":\"10.1155/2020/3954165\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Erdheim-Chester disease is a rare inflammatory disease that infiltrates skeletal and extra-skeletal tissue. Chronic kidney disease (CKD) in Erdheim-Chester disease is usually attributed to retroperitoneal lesions that lead to urologic obstruction and hydronephrosis. In this report, we describe a patient diagnosed with Erdheim-Chester disease who eventually developed end-stage kidney disease (ESKD). After complete remission of Erdheim-Chester disease by vemurafenib therapy and 2 years of hemodialysis, the patient underwent a deceased donor kidney transplantation with basiliximab induction and tacrolimus/mycophenolic acid maintenance. After conversion of mycophenolic acid to azathioprine due to cost, acute cellular rejection had occurred, and he was treated with steroid therapy. The patient remained in complete remission from Erdheim-Chester disease and dialysis-free 16 months after transplant. Kidney transplantation is another treatment option for those patients with Erdheim-Chester disease who suffer from renal failure in the setting of complete remission.</p>\",\"PeriodicalId\":30327,\"journal\":{\"name\":\"Case Reports in Transplantation\",\"volume\":\"2020 \",\"pages\":\"3954165\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-07-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2020/3954165\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Case Reports in Transplantation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2020/3954165\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Transplantation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2020/3954165","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7

摘要

埃尔德海姆-切斯特病是一种罕见的炎性疾病,浸润骨骼和骨骼外组织。埃尔德海姆-切斯特病中的慢性肾脏疾病(CKD)通常归因于腹膜后病变,导致泌尿系统阻塞和肾积水。在本报告中,我们描述了一位被诊断为Erdheim-Chester病的患者最终发展为终末期肾脏疾病(ESKD)。在通过vemurafenib治疗和2年血液透析完全缓解Erdheim-Chester病后,患者在basiliximab诱导和他克莫司/霉酚酸维持下接受了已故供者肾移植。由于成本原因,霉酚酸转化为硫唑嘌呤后,发生了急性细胞排斥反应,患者接受类固醇治疗。患者在移植后16个月仍处于完全缓解和无透析状态。肾移植是另一种治疗选择,对于那些患有Erdheim-Chester病的患者,在完全缓解的情况下遭受肾功能衰竭。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Kidney Transplantation for Erdheim-Chester Disease.

Kidney Transplantation for Erdheim-Chester Disease.

Erdheim-Chester disease is a rare inflammatory disease that infiltrates skeletal and extra-skeletal tissue. Chronic kidney disease (CKD) in Erdheim-Chester disease is usually attributed to retroperitoneal lesions that lead to urologic obstruction and hydronephrosis. In this report, we describe a patient diagnosed with Erdheim-Chester disease who eventually developed end-stage kidney disease (ESKD). After complete remission of Erdheim-Chester disease by vemurafenib therapy and 2 years of hemodialysis, the patient underwent a deceased donor kidney transplantation with basiliximab induction and tacrolimus/mycophenolic acid maintenance. After conversion of mycophenolic acid to azathioprine due to cost, acute cellular rejection had occurred, and he was treated with steroid therapy. The patient remained in complete remission from Erdheim-Chester disease and dialysis-free 16 months after transplant. Kidney transplantation is another treatment option for those patients with Erdheim-Chester disease who suffer from renal failure in the setting of complete remission.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
21
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信